Functional Selectivity in GPCR Heterocomplexes

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 851-855

  Gonzalez Maeso J ^a   Sealfon, S C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Agonist trafficking; Biased agonism; G protein coupled receptor (GPCR); GPCR heteromerization

Indexed keywords

6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; ANTIDEPRESSANT AGENT; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE TRANSFERASE; LIGAND; MESCALINE; PSILOCIN; SEROTONIN 2A RECEPTOR;

ARTICLE; BINDING AFFINITY; BIOPHYSICS; CELL MEMBRANE; CRYSTAL STRUCTURE; CYTOPLASM; DRUG ABUSE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; LABELING INDEX; MAJOR DEPRESSION; MIGRAINE; MOOD DISORDER; MUTAGENESIS; NONHUMAN; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PHOTOCHEMICAL QUENCHING; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; SOMATOSENSORY CORTEX;

BIOLOGICAL AGENTS; HUMANS; LIGANDS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84862836529     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712800959152     Document Type: Article

References (56)

1. Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci, 1995, 16, 232-238.
2. Kenakin, T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol, 2007, 72, 1393-1401.
3. Kenakin, T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther, 2011, 336, 296-302.
4. de Lean, A.; Stadel, J.M.; Lefkowitz, R.J. A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem, 1980, 255, 7108-7117.
5. Kenakin, T. Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov, 2002, 1, 103-110.
6. Nichols, D.E. Hallucinogens. Pharmacol Ther, 2004, 101, 131-181.
7. Fantegrossi, W.E.; Murnane, K.S.; Reissig, C.J. The behavioral pharmacology of hallucinogens. Biochem Pharmacol, 2008, 75, 17-33.
8. Gonzalez-Maeso, J.; Weisstaub, N.V.; Zhou, M.; Chan, P.; Ivic, L.; Ang, R.; Lira, A.; Bradley-Moore, M.; Ge, Y.; Zhou, Q.; Sealfon, S.C.; Gingrich, J.A. Hallucinogens Recruit Specific Cortical 5- HT(2A) Receptor-Mediated Signaling Pathways to Affect Behavior. Neuron, 2007, 53, 439-452.
9. Cussac, D.; Newman-Tancredi, A.; Duqueyroix, D.; Pasteau, V.; Millan, M.J. Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonistdirected trafficking. Mol Pharmacol, 2002, 62, 578-589.
10. Cussac, D.; Boutet-Robinet, E.; Ailhaud, M.C.; Newman-Tancredi, A.; Martel, J.C.; Danty, N.; Rauly-Lestienne, I. Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5- HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol, 2008, 594, 32-38.
11. Rabin, R.A.; Regina, M.; Doat, M.; Winter, J.C. 5-HT2A receptorstimulated phosphoinositide hydrolysis in the stimulus effects of hallucinogens. Pharmacol Biochem Behav, 2002, 72, 29-37.
12. Gonzalez-Maeso, J.; Yuen, T.; Ebersole, B.J.; Wurmbach, E.; Lira, A.; Zhou, M.; Weisstaub, N.; Hen, R.; Gingrich, J.A.; Sealfon, S.C. Transcriptome fingerprints distinguish hallucinogenic and nonhallucinogenic 5-hydroxytryptamine 2A receptor agonist effects in mouse somatosensory cortex. J Neurosci, 2003, 23, 8836-8843.
13. Canal, C.E.; Olaghere da Silva, U.B.; Gresch, P.J.; Watt, E.E.; Sanders-Bush, E.; Airey, D.C. The serotonin 2C receptor potently modulates the head-twitch response in mice induced by a phenethylamine hallucinogen. Psychopharmacol. (Berl), 2010, 209, 163-174.
14. Urban, J.D.; Clarke, W.P.; von Zastrow, M.; Nichols, D.E.; Kobilka, B.; Weinstein, H.; Javitch, J.A.; Roth, B.L.; Christopoulos, A.; Sexton, P.M.; Miller, K.J.; Spedding, M.; Mailman, R.B. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther, 2007, 320, 1-13.
15. Gonzalez-Maeso, J.; Sealfon, S.C. Agonist-trafficking and hallucinogens. Curr Med Chem, 2009, 16, 1017-1027.
16. Mailman, R.B. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci, 2007, 28, 390-396.
17. Milligan, G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol, 2009,
18. Prezeau, L.; Rives, M.L.; Comps-Agrar, L.; Maurel, D.; Kniazeff, J.; Pin, J.P. Functional crosstalk between GPCRs: with or without oligomerization. Curr Opin Pharmacol, 2010, 10, 6-13.
19. Gonzalez-Maeso, J. GPCR oligomers in pharmacology and signaling. Mol Brain, 2011, 4, 20.
20. Kobilka, B.K. Structural insights into adrenergic receptor function and pharmacology. Trends Pharmacol Sci, 2011, 32, 213-218.
21. Peleg, G.; Ghanouni, P.; Kobilka, B.K.; Zare, R.N. Single-molecule spectroscopy of the beta(2) adrenergic receptor: observation of conformational substates in a membrane protein. Proc Natl Acad Sci U S A, 2001, 98, 8469-8474.
22. Ghanouni, P.; Gryczynski, Z.; Steenhuis, J.J.; Lee, T.W.; Farrens, D.L.; Lakowicz, J.R.; Kobilka, B.K. Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem, 2001, 276, 24433-24436.
23. Yao, X.; Parnot, C.; Deupi, X.; Ratnala, V.R.; Swaminath, G.; Farrens, D.; Kobilka, B. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor. Nat Chem Biol, 2006, 2, 417-422.
24. Rasmussen, S.G.; Choi, H.J.; Fung, J.J.; Pardon, E.; Casarosa, P.; Chae, P.S.; Devree, B.T.; Rosenbaum, D.M.; Thian, F.S.; Kobilka, T.S.; Schnapp, A.; Konetzki, I.; Sunahara, R.K.; Gellman, S.H.; Pautsch, A.; Steyaert, J.; Weis, W.I.; Kobilka, B.K. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature, 2011, 469, 175-180.
25. Rosenbaum, D.M.; Zhang, C.; Lyons, J.A.; Holl, R.; Aragao, D.; Arlow, D.H.; Rasmussen, S.G.; Choi, H.J.; Devree, B.T.; Sunahara, R.K.; Chae, P.S.; Gellman, S.H.; Dror, R.O.; Shaw, D.E.; Weis, W.I.; Caffrey, M.; Gmeiner, P.; Kobilka, B.K. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature, 2011, 469, 236-240.
26. Rasmussen, S.G.; Choi, H.J.; Rosenbaum, D.M.; Kobilka, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.; Sanishvili, R.; Fischetti, R.F.; Schertler, G.F.; Weis, W.I.; Kobilka, B.K. Crystal structure of the human beta2 adrenergic G-proteincoupled receptor. Nature, 2007, 450, 383-387.
27. Standfuss, J.; Edwards, P.C.; D'Antona, A.; Fransen, M.; Xie, G.; Oprian, D.D.; Schertler, G.F. The structural basis of agonistinduced activation in constitutively active rhodopsin. Nature, 2011, 471, 656-660.
28. Rosenbaum, D.M.; Cherezov, V.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Yao, X.J.; Weis, W.I.; Stevens, R.C.; Kobilka, B.K. GPCR engineering yields highresolution structural insights into beta2-adrenergic receptor function. Science, 2007, 318, 1266-1273.
29. Warne, T.; Serrano-Vega, M.J.; Baker, J.G.; Moukhametzianov, R.; Edwards, P.C.; Henderson, R.; Leslie, A.G.; Tate, C.G.; Schertler, G.F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491.
30. Bokoch, M.P.; Zou, Y.; Rasmussen, S.G.; Liu, C.W.; Nygaard, R.; Rosenbaum, D.M.; Fung, J.J.; Choi, H.J.; Thian, F.S.; Kobilka, T.S.; Puglisi, J.D.; Weis, W.I.; Pardo, L.; Prosser, R.S.; Mueller, L.; Kobilka, B.K. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature, 2010, 463, 108-112.
31. Warne, T.; Moukhametzianov, R.; Baker, J.G.; Nehme, R.; Edwards, P.C.; Leslie, A.G.; Schertler, G.F.; Tate, C.G. The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor. Nature, 2011, 469, 241-244.
32. Granier, S.; Kim, S.; Shafer, A.M.; Ratnala, V.R.; Fung, J.J.; Zare, R.N.; Kobilka, B. Structure and conformational changes in the Cterminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies. J Biol Chem, 2007, 282, 13895-13905.
33. Elson, E.L.; Fried, E.; Dolbow, J.E.; Genin, G.M. Phase separation in biological membranes: integration of theory and experiment. Annu Rev Biophys, 2010, 39, 207-226.
34. Worgall, T.S. Regulation of lipid metabolism by sphingolipids. Subcell Biochem, 2008, 49, 371-385.
35. Zheng, H.; Chu, J.; Qiu, Y.; Loh, H.H.; Law, P.Y. Agonistselective signaling is determined by the receptor location within the membrane domains. Proc Natl Acad Sci U S A, 2008, 105, 9421-9426.
36. Pradhan, A.A.; Walwyn, W.; Nozaki, C.; Filliol, D.; Erbs, E.; Matifas, A.; Evans, C.; Kieffer, B.L. Ligand-directed trafficking of the delta-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci, 2010, 30, 16459-16468.
37. Jankovic, J.; Stacy, M. Medical management of levodopaassociated motor complications in patients with Parkinson's disease. CNS Drugs, 2007, 21, 677-692.
38. Tfelt-Hansen, P.C.; Koehler, P.J. One hundred years of migraine research: major clinical and scientific observations from 1910 to 2010. Headache, 2010, 51, 752-778.
39. Schmid, C.L.; Raehal, K.M.; Bohn, L.M. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci U S A, 2008, 105, 1079-1084.
40. Schmid, C.L.; Bohn, L.M. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ss-arrestin2/Src/Akt signaling complex in vivo. J Neurosci, 2010, 30, 13513-13524.
41. Aghajanian, G.K. Modeling psychosis in vitro by inducing disordered neuronal network activity in cortical brain slices. Psychopharmacology (Berl), 2009, 206, 575-585.
42. Marek, G.J. Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition. Eur J Pharmacol, 2010, 639, 81-90.
43. Gonzalez-Maeso, J.; Ang, R.L.; Yuen, T.; Chan, P.; Weisstaub, N.V.; Lopez-Gimenez, J.F.; Zhou, M.; Okawa, Y.; Callado, L.F.; Milligan, G.; Gingrich, J.A.; Filizola, M.; Meana, J.J.; Sealfon, S.C. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature, 2008, 452, 93-97.
44. Rives, M.L.; Vol, C.; Fukazawa, Y.; Tinel, N.; Trinquet, E.; Ayoub, M.A.; Shigemoto, R.; Pin, J.P.; Prezeau, L. Crosstalk between GABAB and mGlu1a receptors reveals new insight into GPCR signal integration. Embo J, 2009, 28, 2195-2208.
45. Moreno, J.L.; Holloway, T.; Albizu, L.; Sealfon, S.C.; Gonzalez-Maeso, J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett, 2011.
46. Sealfon, S.C.; Olanow, C.W. Dopamine receptors: from structure to behavior. Trends Neurosci, 2000, 23, S34-S40.
47. Iversen, S.D.; Iversen, L.L. Dopamine: 50 years in perspective. Trends Neurosci, 2007, 30, 188-193.
48. Strange, P.G. Antipsychotic drug action: antagonism, inverse agonism or partial agonism. Trends Pharmacol Sci, 2008, 29, 314-321.
49. Perreault, M.L.; Hasbi, A.; Alijaniaram, M.; Fan, T.; Varghese, G.; Fletcher, P.J.; Seeman, P.; O'Dowd, B.F.; George, S.R. The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. J Biol Chem, 2010, 285, 36625-36634.
50. Hasbi, A.; O'Dowd, B.F.; George, S.R. Dopamine D1-D2 receptor heteromer signaling pathway in brain: Emerging physiological relevance. Mol Brain, 2011, 4, 26.
51. Lee, S.P.; So, C.H.; Rashid, A.J.; Varghese, G.; Cheng, R.; Lanca, A.J.; O'Dowd, B.F.; George, S.R. Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem, 2004, 279, 35671-35678.
52. Verma, V.; Hasbi, A.; O'Dowd, B.F.; George, S.R. Dopamine D1-D2 receptor Heteromer-mediated calcium release is desensitized by D1 receptor occupancy with or without signal activation: dual functional regulation by G protein-coupled receptor kinase 2. J Biol Chem, 2010, 285, 35092-35103.
53. Rashid, A.J.; So, C.H.; Kong, M.M.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B.F.; George, S.R. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A, 2007, 104, 654-659.
54. Pei, L.; Li, S.; Wang, M.; Diwan, M.; Anisman, H.; Fletcher, P.J.; Nobrega, J.N.; Liu, F. Uncoupling the dopamine D1-D2 receptor complex exerts antidepressant-like effects. Nat Med, 2010, 16, 1393-1395.
55. Vikis, H.G.; Guan, K.L. Glutathione-S-transferase-fusion based assays for studying protein-protein interactions. Methods Mol Biol, 2004, 261, 175-186.
56. Nestler, E.J.; Hyman, S.E. Animal models of neuropsychiatric disorders. Nat Neurosci, 2010, 13, 1161-1169.